Renal involvement of monoclonal immunoglobulin deposition disease associated with an unusual monoclonal immunoglobulin A glycan profile.
A 38-year-old man was admitted to the hospital for the evaluation of proteinuria, microscopic hematuria, and monoclonal IgA-kappa gammopathy. The initial renal pathological findings showed mesangial proliferative glomerulonephritis with endocapillary proliferation, a necrotizing lesion, and cellular crescent formation accompanied by IgA1-kappa deposition in the mesangium. Neither typical immune-complex deposits nor organized-structure deposits were detected. We diagnosed the patient with monoclonal immunoglobulin deposition disease (MIDD) associated with monoclonal IgA (mIgA). After the initiation of a monthly treatment with melphalan and predonisolone (MP therapy), the patient's serum IgA levels declined, and clinical remission was ultimately achieved. The follow-up renal biopsy showed reduced IgA-kappa staining, and both the endocapillary proliferation and the necrotizing lesion had disappeared. To elucidate the mechanism of IgA deposition, we investigated the glycan profile of the patient's serum mIgA using a mass spectrometry technique. The results revealed an unusual N-glycan profile compared to that of another patient with circulating mIgA lacking renal involvement and that of a healthy control. mIgA deposition in the mesangial area is a rare disease, and the glycan profiling of MIDD with renal involvement has not been reported previously. Thus, the present case suggests that any variation in Ig glycosylation may be a step in the pathogenesis of MIDD with renal involvement and/or contribute to some cases of IgA nephropathy.
Kaneko
Syuzou
S
Department of Nephrology, University of Tsukuba, Japan.
Usui
Joichi
J
Narimatsu
Yoshiki
Y
Ito
Hiromi
H
Narimatsu
Hisashi
H
Hagiwara
Masahiro
M
Tsuruoka
Shuichi
S
Nagata
Michio
M
Yamagata
Kunihiro
K
D000328:Adult; D004359:Drug Therapy, Combination; D005920:Glomerular Mesangium / Q000276:immunology* / Q000473:pathology; D015432:Glomerulonephritis, Membranoproliferative / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D005938:Glucocorticoids / Q000627:therapeutic use; D006031:Glycosylation; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis* / Q000097:blood; D007145:Immunoglobulin kappa-Chains / Q000032:analysis* / Q000097:blood; D008297:Male; D013058:Mass Spectrometry; D008558:Melphalan / Q000627:therapeutic use; D010265:Paraproteinemias / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D011134:Polysaccharides / Q000032:analysis* / Q000097:blood; D011239:Prednisolone / Q000627:therapeutic use; D011499:Protein Processing, Post-Translational; D016896:Treatment Outcome
D005938:Glucocorticoids; D007070:Immunoglobulin A; D007145:Immunoglobulin kappa-Chains; D011134:Polysaccharides; D011239:Prednisolone; D008558:Melphalan
J Am Soc Nephrol. 1996 Jun;7(6):955-60
8793806
Expert Rev Proteomics. 2005 Jan;2(1):87-101
15966855
Mayo Clin Proc. 2007 Dec;82(12):1468-73
18053453
Am J Kidney Dis. 2006 Feb;47(2):342-9
16431264
Blood. 2003 Nov 15;102(10):3759-64
12881316
Biochem Biophys Res Commun. 1999 Aug 2;261(2):472-7
10425209
Arthritis Rheum. 2006 Nov;54(11):3433-40
17075835
Hum Pathol. 1985 Mar;16(3):294-304
3918930
Mass Spectrom Rev. 2004 May-Jun;23(3):161-227
14966796
Am J Kidney Dis. 2003 Mar;41(3):558-64
12612978
Mayo Clin Proc. 2007 Dec;82(12):1474-9
18053454
Am J Kidney Dis. 2000 Sep;36(3):E19
10977812
Kidney Int. 2004 Jan;65(1):85-96
14675039
Br J Haematol. 2003 Sep;122(6):915-7
12956761
Am J Pathol. 2007 Feb;170(2):447-56
17255313
Science. 2001 Mar 23;291(5512):2351-6
11269315
J Proteome Res. 2009 Mar;8(3):1358-67
19178301
J Am Soc Nephrol. 1998 Nov;9(11):2048-54
9808090
J Am Chem Soc. 2003 Dec 31;125(52):16213-9
14692762
Nephrol Dial Transplant. 2008 Dec;23(12):3888-94
18596130
Clin Exp Nephrol. 2010 Feb;14(1):90-3
19795180